Aquestive Therapeutics (AQST) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics (AQSTResearch Report) today and set a price target of $31.00. The company’s shares closed last Monday at $5.02.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 8.6% and a 51.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.00, a 257.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.

See today’s analyst top recommended stocks >>

Based on Aquestive Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.77 million and GAAP net loss of $16.53 million. In comparison, last year the company earned revenue of $12.64 million and had a GAAP net loss of $14.73 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.